| Rank |
Status |
Study |
| 1 |
Recruiting
|
Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome
| Condition: |
Precancerous Condition |
| Interventions: |
Drug: Naproxen; Other: placebo; Other: laboratory biomarker analysis |
| Outcome Measures: |
Change in PGE2 concentration levels in normal colorectal mucosa; Minimal biologically effective dose of Naproxen defined by modulation of PGE2 levels; Response defined as >= 30% reduction in PGE2 levels; Incidence of toxicity graded according to National Cancer Institute Common Criteria for Adverse Events (NCI CTCAE) version 4.0; Naproxen concentrations in plasma samples; Naproxen concentrations in normal colorectal mucosa; PGE-M levels in urine samples; Change in number of polyps observed in the rectosigmoid area; Changes in the microRNA profile of the normal colorectal mucosa; Changes in gene expression mRNA profiles of the normal colorectal mucosa; Changes in the mutational rate of the normal colorectal mucosa |
|
| 2 |
Unknown †
|
Trial of Naproxen to Evaluate Various Methods of Measuring Analgesic Effect in Osteoarthritis Pain of the Knee
| Condition: |
Osteoarthritis, Knee |
| Interventions: |
Drug: Naproxen; Drug: Placebo |
| Outcome Measures: |
Efficacy of Naproxen vs. placebo; Safety |
|
| 3 |
Not yet recruiting
|
Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine.
| Conditions: |
Migraine; Headache |
| Interventions: |
Drug: naratriptan + Naproxen; Drug: naratriptan; Drug: Naproxen |
| Outcome Measures: |
Headache relief 2 hours after dosing, without use of rescue medication; Headache relief 4 hours after dosing, without use of rescue medication; Maintenance of pain relief between 2 and 24 hours after dosing, without use of rescue medication; Pain-free response 2 and 4 hours after dosing, without use of rescue medication; Maintenance of pain-free response between 2 and 24 hours, without use of rescue medication; Freedom from nausea, vomiting, photophobia and phonophobia 2 and 4 hours after dosing; Maintenance of freedom from nausea, vomiting, photophobia and phonophobia between 2 and 24 hours after dosing, without use of rescue medication; Recurrence of pain between 2 and 24 hours after dosing, without use of rescue medication; Proportion of subjects who used rescue medication between 2 and 24 hours after dosing, at least once; Safety descriptive about occurence of adverse events, evaluation of results of general physical examination. |
|
| 4 |
Unknown †
|
Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine
| Conditions: |
Migraine; Headache |
| Interventions: |
Drug: Fixed-dose combination of naratriptan + Naproxen; Drug: Naratriptan; Drug: Naproxen |
| Outcome Measures: |
Headache relief 2 hours after dosing, without use of rescue medication.; Headache relief 4 hours after dosing, without use of rescue medication; Sustained headache relief over 24 hours, without use of rescue medication; Pain-free response 2 and 4 hours after dosing, without use of rescue medication; Sustained pain-free response over 24 hours, without use of rescue medication; Freedom from photophobia, phonophobia and nausea 2 and 4 hours after dosing, without use of rescue medication; Sustained freedom from photophobia, phonophobia and nausea from 2 through 24 hours after dosing, without use of rescue medication; Proportion of subjects who used rescue medication between 2 and 24 hours after dosing, at least once; Safety descriptive about occurence of adverse events, evaluation of results of general physical examination. |
|
| 5 |
Recruiting
|
Celecoxib Versus Naproxen for Prevention of Recurrent Ulcer Bleeding in Arthritis Patients
| Conditions: |
Arthritis; Cardiovascular Diseases; Cerebrovascular Disorders |
| Interventions: |
Drug: Celecoxib(drug); Drug: Naproxen(drug) |
| Outcome Measures: |
Recurrent ulcer bleeding within 78 weeks according to pre-specified criteria; Cardiovascular events |
|
| 6 |
Recruiting
|
NOLAN: Naproxen or Loratadine and Neulasta
| Condition: |
Bone Pain in Stage I - III Breast Cancer |
| Interventions: |
Drug: Naproxen; Drug: Loratadine |
| Outcome Measures: |
Bone pain (all grade) in cycle 1; Bone pain (all grade) by cycle (2-4) and across cycles; Severe (grade 3/4) bone pain by cycle and across cycles; Subject reported bone pain; Maximum Subject Reported bone pain; Area under the Curve for subject-reported bone pain; Adverse Event and Serious Adverse Events; Severity of Adverse Events |
|
| 7 |
Unknown †
|
Naproxen for Acute Pain After Surgery: A Randomized, Placebo-Controlled Trial
| Condition: |
Pain, Postoperative |
| Interventions: |
Drug: Naproxen; Drug: placebo |
| Outcome Measures: |
cumulative opiate dose administered, as recorded on the computerized medication administration record (CMAR); patient reported pain scores; side effects of study medication and opiate analgesia |
|
| 8 |
Recruiting
|
The Effect of Non-Steroidal Anti-Inflammatory Drug Naproxen on Pleural Effusion Formation After Lung Resection
| Conditions: |
Pleural Effusion; Pleural Effusion Malignant |
| Interventions: |
Drug: Naproxen; Drug: Placebo |
| Outcome Measures: |
Change in volume of pleural effusion collected; Hospital length of stay; compared between intervention and control arms; Gastrointestinal complications; General re-admission rates; Total number of days chest tubes remain in-situ |
|
| 9 |
Recruiting
|
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen
| Condition: |
Arthritis, Rheumatoid |
| Interventions: |
Drug: celecoxib; Drug: Ibuprofen; Drug: Naproxen |
| Outcome Measures: |
The first occurrence of cardiovascular death (including hemorrhagic death), non-fatal myocardial infarction, or non-fatal stroke (APTC composite endpoint).; The occurrence of Clinical Significant Gastrointestinal Events (CSGIEs); Patient's Assessment of Arthritis Pain (VAS); The first occurrence of a MACE defined as the composite of cardiovascular death (including hemorrhagic death), non-fatal MI, non-fatal stroke, hospitalization for UA, revascularization or hospitalization for TIA |
|
| 10 |
Not yet recruiting
|
Effect of L-dopa In Subacute Back Pain Population
| Condition: |
Sub-acute Back Pain |
| Interventions: |
Drug: Naproxen; Drug: Carbidopa/Levodopa; Drug: Placebo |
| Outcome Measure: |
VAS pain scale |
|
| 11 |
Not yet recruiting
|
Colchicine Or Naproxen Treatment for ACute gouT
| Condition: |
Gout |
| Interventions: |
Drug: Low-dose colchicine; Drug: Naproxen |
| Outcome Measure: |
Change in pain intensity |
|
| 12 |
Not yet recruiting
|
Efficacy of Co-administration of an NSAID With a Dopamine Agonist In Healthy Subjects
| Condition: |
Acute Pain |
| Interventions: |
Drug: Naproxen; Drug: Sinemet; Drug: Placebo |
| Outcome Measure: |
VAS pain scale |
|
| 13 |
Recruiting
|
Efficacy of Sumatriptan With Naprosyn in Migraine With Aura
| Condition: |
Migraine With Aura |
| Interventions: |
Drug: sumatriptan with naprosyn; Drug: placebo |
| Outcome Measures: |
Primary outcome measure will be comparative percentage of patients pain free at 2 and 4 hours from initiating treatment with placebo vs treatment with Treximet (sumatriptan with naprosyn).; Secondary outcomes will be percentage of patients with pain relief at 2 and 4 hours. |
|
| 14 |
Recruiting
|
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
| Condition: |
Juvenile Idiopathic Arthritis (JIA) |
| Interventions: |
Drug: VIMOVO 250/20; Drug: VIMOVO 375/20; Drug: VIMOVO 500/20 |
| Outcome Measures: |
Incidence of severity of AEs and SAEs.; Change in serum iron/total iron binding capacity (serum iron/TIBC), Vitamin B12, and magnesium.; Change from baseline in vital signs, physical examination results and clinical laboratory tests.; Pharmacokinetic (PK) in terms of characteristics of VIMOVO (Naproxen / esomeprazole). |
|
| 15 |
Not yet recruiting
|
Placebo In Chronic Pain
| Condition: |
Chronic Back Pain |
| Interventions: |
Drug: Naproxen; Drug: Placebo; Drug: Omeprazole |
| Outcome Measure: |
VAS pain scale |
|
| 16 |
Recruiting
|
Low Level Laser Therapy Versus Pharmacotherapy in in Improving Masticatory Muscle Pain
| Condition: |
TMD |
| Interventions: |
Radiation: low level laser therapy; Drug: Naproxen |
| Outcome Measure: |
reduction of paim measured by VAS |
|
| 17 |
Recruiting
|
Comparison Of Ketorolac Tromethamine Versus Naproxen For Moderate to Severe Back Pain Treatment
| Condition: |
Back Pain |
| Interventions: |
Drug: Ketorolac Tromethamine; Drug: Naproxen |
| Outcome Measures: |
Efficacy of treatment in back pain relief based on Visual Analog Scale (VAS).; Safety will be evaluated by the adverse events occurrences |
|
| 18 |
Not yet recruiting
|
Comparison Of Ketorolac Tromethamine Oral Drops Versus Naproxen For Moderate to Severe Back Pain Treatment
| Condition: |
Back Pain |
| Interventions: |
Drug: Ketorolac Tromethamine; Drug: Naproxen |
| Outcome Measures: |
Efficacy of treatment in back pain relief based on Visual Analogic Score (VAS).; Safety will be evaluated by the adverse events occurrences |
|
| 19 |
Recruiting
|
A Randomized Study of Three Medication Regimens for Acute Low Back Pain
| Condition: |
Acute Low Back Pain |
| Interventions: |
Drug: Naproxen; Drug: Cyclobenzaprine; Drug: Oxycodone/ acetaminophen |
| Outcome Measure: |
Roland Morris low back pain functional disability scale |
|
| 20 |
Unknown †
|
Ictal and Interictal Inflammatory Markers in Migraine
| Condition: |
Migraine |
| Interventions: |
Drug: sumatriptan/Naproxen sodium; Drug: Placebo |
| Outcome Measure: |
Blood levels of proteins will be evaluated at baseline when subjects are pain-free and then repeated during an acute attack, both prior to drug administration and then at 30 minutes, 1 hour and 2 hours after acute treatment. |
|
